Home Oncimmune Holdings plc

Oncimmune Holdings plc

Oncimmune Signs Commercialization Partnership In Russia

This commercial partnership with R-Pharm is for an initial term of five years and will generate revenues of at least £5 million, including milestone payments of £2.75 million during this period. R-Pharm will commercialize EarlyCDT Lung in both lung cancer screening and nodule risk assessment in the region.

Must Read

New Study Validates Rigorous Safety Measures Needed To Reduce Mercury Exposure During Dental Amalgam Filling Removal

"For decades, our non-profit organization has been concerned about this issue and collected research about amalgam fillings, all of which contain approximately 50% mercury, a known neurotoxin," explains IAOMT President Michael Rehme, DDS, NMD.  "Based on this science, we have strongly recommended that safety measures be enacted for dental procedures involving these silver-colored fillings, and we have also intensely advocated for the end of dental amalgam usage."